PDCL Antibody

What is PDCL antibody and what is its target protein?

PDCL antibody targets phosducin-like protein, which has a calculated molecular weight of approximately 34 kDa (301 amino acids), though the observed molecular weight in experimental conditions typically ranges from 40-42 kDa. The antibody recognizes this protein in various applications such as Western blot, IHC, and ELISA. PDCL (phosducin-like) is the gene symbol with NCBI gene ID 5082, and the protein is referenced under UniProt ID Q13371 .

What species reactivity has been confirmed for PDCL antibody?

PDCL antibody demonstrates confirmed reactivity with human, mouse, and rat samples as determined through systematic testing. Specific publications have cited reactivity in rat models, particularly in brain tissue studies. When selecting this antibody for cross-species applications, it's important to note that the antibody (16057-1-AP) is generated as a rabbit polyclonal antibody using a PDCL fusion protein (Ag9029) as the immunogen .

What is the molecular structure and form of commercially available PDCL antibody?

The PDCL antibody is typically available as an unconjugated, liquid formulation purified through antigen affinity methods. It is commonly preserved in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. The antibody belongs to the IgG class and is available in polyclonal form. For research purposes, it's critical to understand this structure when planning experimental applications, particularly when considering potential interactions with other reagents or when performing specialized techniques such as immunoprecipitation .

What are the recommended applications for PDCL antibody?

PDCL antibody has been validated for multiple research applications including Western Blot (WB), Immunohistochemistry (IHC), and ELISA. For Western Blot applications, the recommended dilution range is 1:1000-1:6000, while for IHC applications, the recommended dilution range is 1:50-1:500. It is important to note that optimal dilutions may be sample-dependent, and researchers should conduct preliminary titration experiments to determine the optimal concentration for their specific experimental system .

How should PDCL antibody be stored to maintain its activity?

The optimal storage condition for PDCL antibody is at -20°C, where it remains stable for up to one year after shipment. Notably, for the specific product referenced (16057-1-AP), aliquoting is generally unnecessary for -20°C storage due to the formulation with 50% glycerol, which prevents freeze-thaw damage. Smaller volume products (20μl sizes) may contain 0.1% BSA as a stabilizing agent. When handling the antibody, minimize repeated freeze-thaw cycles, and avoid prolonged exposure to ambient temperatures to maintain optimal binding activity and specificity .

What cell lines and tissues have been validated for PDCL antibody use?

PDCL antibody has been positively validated in Western blot applications using HEK-293 cells, NCI-H1299 cells, and Jurkat cells. For IHC applications, positive detection has been confirmed in human placenta tissue and mouse brain tissue. These validations provide researchers with confidence when working with these specific experimental models. When using different cell lines or tissues, preliminary validation is recommended to ensure antibody performance in the specific experimental context .

How can researchers optimize PDCL antibody performance in Western blot applications?

To optimize PDCL antibody performance in Western blot applications, researchers should consider several factors. First, the dilution range of 1:1000-1:6000 provides a starting point, but optimization for specific sample types is essential. When detecting PDCL protein, researchers should look for bands at 40-42 kDa, which is slightly higher than the calculated molecular weight (34 kDa). This discrepancy may be due to post-translational modifications or the presence of protein complexes. Following the manufacturer's detailed Western blot protocol is recommended, particularly regarding blocking agents, incubation times, and washing steps to minimize background and maximize specific signal .

What considerations should be made when using PDCL antibody across different species?

When using PDCL antibody across different species, researchers should be aware that while the antibody shows reactivity with human, mouse, and rat samples, the efficiency of binding may vary. The antibody was generated using a fusion protein as the immunogen, which may affect epitope recognition across species. For cross-species applications, researchers should first validate the antibody in their specific model system by running appropriate controls. Additionally, optimization of antibody concentration and incubation conditions may be necessary when transitioning between species to account for potential differences in epitope conservation and accessibility .

How can PDCL antibody be integrated into multi-omics research approaches?

Integrating PDCL antibody into multi-omics research requires careful consideration of complementary techniques. While traditional applications like Western blot and IHC provide information about protein expression and localization, combining these with genomic or transcriptomic data can provide more comprehensive insights. For instance, researchers might correlate PDCL protein expression (detected via antibody) with mRNA levels or gene alterations. Similar to approaches used in PD-1 monoclonal antibody research, digital spatial profiling and multiplex immunofluorescence can be employed with PDCL antibody to analyze spatial organization of PDCL in relation to other proteins of interest, particularly in complex tissue environments .

What are the considerations for using PDCL antibody in studies investigating protein-protein interactions?

When using PDCL antibody for protein-protein interaction studies, researchers must consider several factors. First, the polyclonal nature of the available antibody (16057-1-AP) means it recognizes multiple epitopes, which can be advantageous for detecting native protein but may potentially interfere with certain protein-protein binding sites. For co-immunoprecipitation experiments, researchers should validate that the antibody does not disrupt the interaction of interest. Additionally, crosslinking approaches may be necessary to capture transient interactions. Controls should include immunoprecipitation with non-specific IgG and validation of interactions through reciprocal co-immunoprecipitation when possible .

How can researchers employ PDCL antibody in the context of neurodegenerative disease studies?

Given the positive detection of PDCL in mouse brain tissue, researchers investigating neurodegenerative diseases may find this antibody particularly valuable. When designing such studies, researchers should consider using the antibody in combination with markers for specific neural cell types or pathological features. The recommended IHC protocols with TE buffer (pH 9.0) for antigen retrieval are particularly relevant for brain tissue sections. For studies examining changes in PDCL expression or localization during disease progression, quantitative approaches such as digital image analysis of IHC staining or quantitative Western blot should be employed. Additionally, researchers should consider analyzing PDCL in different brain regions relevant to the specific neurodegenerative condition being studied .

What are common challenges when using PDCL antibody in IHC applications and how can they be addressed?

When using PDCL antibody in IHC applications, researchers may encounter several common challenges. First, background staining can be problematic, particularly in highly vascularized tissues. To address this, optimization of antibody dilution within the recommended range (1:50-1:500) is essential. Additionally, extending blocking steps or using alternative blocking reagents may help reduce non-specific binding. Second, inconsistent staining across tissue sections may occur, which can be addressed by ensuring uniform antigen retrieval conditions and antibody exposure. For formalin-fixed tissues with suboptimal results, extending the antigen retrieval time using TE buffer at pH 9.0 may improve epitope accessibility. Finally, when interpreting results, researchers should always include appropriate positive controls (such as human placenta or mouse brain tissue) and negative controls (omitting primary antibody) .

How should researchers interpret discrepancies between calculated and observed molecular weights when using PDCL antibody?

The observed molecular weight of PDCL protein (40-42 kDa) is higher than the calculated molecular weight (34 kDa), which represents a common scenario in protein research. This discrepancy may be attributed to several factors: post-translational modifications (such as phosphorylation or glycosylation), the presence of splice variants, or incomplete denaturation during sample preparation. When interpreting Western blot results, researchers should be aware of this size difference and not mistake it for non-specific binding. To confirm band specificity, researchers can employ additional techniques such as siRNA knockdown of PDCL, followed by Western blot to demonstrate reduced band intensity. Alternative approaches include using a different antibody targeting a different epitope of PDCL to confirm the observed molecular weight .

What methodological approaches can address potential cross-reactivity issues with PDCL antibody?

To address potential cross-reactivity issues with PDCL antibody, researchers should implement several methodological approaches. First, comprehensive blocking strategies using BSA or non-fat milk should be optimized to minimize non-specific binding. Second, stringent washing protocols with appropriate detergent concentrations should be employed to remove weakly bound antibodies. For critical applications where absolute specificity is required, validation using PDCL knockout or knockdown models provides the most definitive evidence of antibody specificity. Additionally, pre-adsorption tests using the immunizing peptide can be performed to confirm specificity. When analyzing complex samples with potential homologous proteins, researchers should be particularly vigilant about validating bands or staining patterns through complementary techniques such as mass spectrometry or immunoprecipitation followed by Western blot .

How can PDCL antibody be utilized in de novo antibody design research?

While PDCL antibody itself is a research tool, studying its binding characteristics can inform de novo antibody design approaches. Researchers investigating antibody engineering could analyze the epitope-binding properties of PDCL antibody to understand structure-function relationships. Modern computational approaches, similar to those described for OptCDR (Optimal Complementarity Determining Regions), could be applied to optimize PDCL antibody binding. These methods use canonical structures to generate CDR backbone conformations that interact favorably with targets. Researchers could apply such computational methods to modify the existing PDCL antibody to enhance its binding affinity, specificity, or functionality for specialized applications. This approach represents a systematic design method that reduces reliance on extensive screening and immunization protocols .

What considerations exist for using PDCL antibody in multiplex imaging and spatial proteomics?

When incorporating PDCL antibody into multiplex imaging and spatial proteomics workflows, researchers must address several methodological considerations. First, compatibility with other antibodies in the multiplex panel should be verified, particularly regarding species origin to avoid cross-reactivity between secondary antibodies. The polyclonal nature of PDCL antibody (16057-1-AP) provides good signal amplification but may complicate highly multiplexed approaches. For cyclic immunofluorescence methods, researchers should validate that the PDCL antibody signal can be effectively quenched between cycles. When combining with techniques like digital spatial profiling (similar to approaches used in PD-1 mAb studies), optimization of antibody concentration is critical to ensure balanced signal across all markers in the panel. Additionally, proper controls should be implemented to account for potential autofluorescence, particularly in tissues like brain where lipofuscin can interfere with fluorescent detection .

How can artificial intelligence approaches enhance data interpretation when using PDCL antibody in complex research contexts?

Artificial intelligence (AI) approaches offer significant potential for enhancing data interpretation when using PDCL antibody in complex research contexts. Similar to the artificial neural network (ANN) model described for predicting responses to PD-1 monoclonal antibody treatment, researchers could develop AI models to analyze PDCL staining patterns in relation to disease states or experimental conditions. For IHC applications, convolutional neural networks could be trained to quantify PDCL expression levels across tissue sections, identify subcellular localization patterns, or detect co-localization with other markers. In Western blot analysis, AI algorithms could improve band quantification accuracy, particularly when dealing with complex samples or background issues. When integrating PDCL antibody data with other -omics datasets, machine learning approaches can identify non-obvious correlations between PDCL expression patterns and genomic alterations, transcriptomic profiles, or clinical outcomes. To implement such approaches, researchers should establish standardized protocols for data acquisition to ensure consistency across samples and generate sufficient training data for the AI models .